Clinical Trial Update: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating autologous stem cell transplant after a rituximab/ibrutinib/arac-containing induction in generalized mantle cell lymphoma is c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Ibrutinib (ibrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Prof. Dr. M. Dreyling (co-chairman) | Conditions: Mantle Cell Lymphoma | Phase 3 | Status: RECRUITING